RxDoctor Payments Data

Darren McDow, MD

Internal Medicine · Los Angeles, CANPI 1710905948

Payments from drug & device makers

$2,355in general payments, 2019–2025

Across 93 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$604
  • Johnson & Johnson$559
  • Novartis$235
  • Lilly USA, LLC$220
  • Sanofi-aventis U.S. LLC$175
  • Pfizer$132
  • plus $429 from 8 others

What the payments were for

  • Food & beverage$2,355100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,355 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$23,234
Medicare patients
72
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$43,082
EliquisApixaban57$35,073
JanuviaSitagliptin Phosphate19$19,116
MounjaroTirzepatide12$18,748
JanumetSitagliptin Phos/Metformin Hcl19$16,848
Soliqua 100-33Insulin Glargine/Lixisenatide13$15,127
FarxigaDapagliflozin Propanediol17$14,788
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,022
EntrestoSacubitril/Valsartan13$9,591
AliskirenAliskiren Hemifumarate12$2,953
Nano 2nd Gen Pen NeedlePen Needle, Diabetic19$2,550
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,096
Potassium Chloride33$1,980
Raloxifene Hcl12$1,950
Humalog Kwikpen U-100Insulin Lispro16$1,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$604$43,08224 claims
MerckJanuvia, Janumet$53$35,96438 claims
PfizerEliquis$132$35,07357 claims
Lilly USA, LLCMounjaro$220$18,74812 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$175$15,12713 claims
AstraZenecaFarxiga$87$14,78817 claims
NovartisEntresto$235$9,59113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →